Top

Published in:

01-08-2010 | Preclinical Study

Reciprocal regulation of ZEB1 and AR in triple negative breast cancer cells

Authors: Tisheeka R. Graham, Rami Yacoub, LaTonia Taliaferro-Smith, Adeboye O. Osunkoya, Valerie A. Odero-Marah, Tongrui Liu, K. Sean Kimbro, Dipali Sharma, Ruth M. O’Regan

Published in: Breast Cancer Research and Treatment | Issue 1/2010

Abstract

Zinc-finger enhancer binding protein (ZEB1) is a transcription factor involved in the progression of cancer primarily through promoting epithelial to mesenchymal transition (EMT). ZEB1 represses the expression of E-cadherin by binding to E-box sequences in the promoter, thus decreasing epithelial differentiation. We show that ZEB1 and androgen receptor (AR) cross-talk in triple negative breast cancer cell lines. Chromatin immunoprecipitation analysis demonstrates that ZEB1 binds directly to the E-box located in the AR promoter. ZEB1 suppression by stably transfecting shRNA in a triple negative breast cancer cell line resulted in a decrease of AR mRNA, protein, and AR downstream targets. ZEB1 knockdown in triple negative breast cancer cells sensitized the cells to bicalutamide by reducing migration compared to the control cells. Conversely, blockade of AR signaling with bicalutamide resulted in a suppression of ZEB1 protein expression in two triple negative breast cancer cell lines. Furthermore, using a breast cancer tissue microarray, a majority of triple negative breast cancers exhibit positive staining for both ZEB1 and AR. Taken together, these results indicate that ZEB1 and AR regulate each other to promote cell migration in triple negative breast cancer cells.

Brys M, Wojcik M, Makowska H, Krajewska W (2002) Androgen receptor status in female breast cancer: RT-PCR and western blot studies. J Cancer Res Clin Oncol 128:85–90CrossRefPubMed

Davidson N, Lippman M (1989) The role of estrogens in growth regulation of breast cancer. Crit Rev Oncog 1:89–111PubMed

Platet N, Cathiard A, Gleizes M, Garcia M (2004) Estrogens and their receptors in breast cancer progression: a dual role in cancer proliferation and invasion. Crit Rev Oncol Hematol 51:55–67CrossRefPubMed

Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF et al (2005) Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years of adjuvant treatment for breast cancer. Lancet 365:60–62CrossRefPubMed

Isola J (1993) Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors. J Pathol 170:31–35CrossRefPubMed

Diaz-Chico B, Rodriguez F, Gonzalez A, Ramirez R, Bilbao C et al (2007) Androgens and androgen receptors in breast cancer. Steroid Biochem Mol Biol 105:1–15CrossRef

Birrell S, Hall R, Tilley W (1998) Role of androgen receptor in human breast cancer. J Mammary Gland Biol Neoplasia 3:95–103CrossRefPubMed

Zhu X, Li H, Liu JP, Funder JW (1999) Androgen stimulates mitogen-activated protein kinase in human breast cancer cells. Mol Cell Endocrinol 152:199–206CrossRefPubMed

Birrell SN, Bentel JM, Hickey TE, Ricciardelli C, Weger MA, Horsfall DJ, Tilley WD (1995) Androgens induced divergent proliferative responses in human breast cancer cell lines. J Steroid Biochem Mol Biol 52:459–467CrossRefPubMed

10.

Doane AS, Danso M, Lal P, Donaton M, Zhang L, Hudis C, Gerald W et al (2006) An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 25:3994–4008CrossRefPubMed

11.

Wong YC, Xie B (2001) The role of androgens I mammary carcinogenesis. Ital J Anat Embryol 106:111–115PubMed

12.

Boccuzzi G, Tamagno E, Brignardello E et al (1995) Growth inhibition of DMBA-induced rat mammary carcinomas by the antiandrogen flutamide. J Cancer Res Clin Oncol 121:150–154CrossRefPubMed

13.

Naderi A, Hughes-Davies L (2008) A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer. Neoplasia 10:542–548PubMed

14.

Eger A, Aigner K, Sonderegger S et al (2005) Delta EF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. Oncogene 24:2375–2385CrossRefPubMed

15.

Ohira T, Gemmill R, Ferguson K et al (2003) WNT7a induces E-cadherin in lung cancer cells. PNAS 100:10429–10434CrossRefPubMed

16.

Spaderna S, Schmalhofer O, Hlubek F, Berx G, Eger A, Merkel S et al (2006) A transient, EMT-linked loss of basement membranes indicates metastasis and poor survival in colorectal cancer. Gastroenterology 131:830–840CrossRefPubMed

17.

Vincent-Salomon A, Theiry JP (2003) Epithelial-mesenchymal transition in breast cancer development. Breast Cancer Res 5:101–106CrossRefPubMed

18.

Chua H, Bhat-Nakshatri P, Clare S, Morimiya A, Badve S, Nakshatri H (2007) NF-κB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB1 and ZEB2. Oncogene 26:711–724

19.

Graham TR, Zhau H, Odero-Marah V, Osunkoya A, Kimbro K et al (2008) Insulin-like growth factor-I-dependent upregulation of ZEB1 drives epithelial to mesenchymal transition in human prostate cancer cells. Cancer Res 68:2479–2488CrossRefPubMed

20.

Postigo A, Dean D (1997) ZEB, a vertebrate homolog of Drosophila Zfh-1, is a negative regulator of muscle differentiation. EMBO J 16:3935–3943CrossRefPubMed

21.

Spaderna S, Schmalhofer O, Wahlbuhl M, Dimmler A, Bauer K et al (2008) The transcriptional repressor ZEB1 promotes metastasis and loss of cell polarity in cancer. Cancer Res 68:537–544CrossRefPubMed

22.

Spoelstra N, Manning N, Higashi Y, Darling D, Singh M, Shroyer K et al (2006) The transcription factor ZEB1 is aberrantly expressed in aggressive uterine cancers. Cancer Res 66:3893–3902CrossRefPubMed

23.

Hope I, Mahadevan S, Struhl K (1998) Structural and functional characterization of the short acidic transcriptional activation domain of yeast GCN4 protein. Nature 333:635–640CrossRef

24.

Seipel K, Georgiev O, Schaffner W (1992) Different activation domains stimulate transcription from remote (“enhancer”) and proximal (“promoter”) positions. EMBO J 11:4961–4968PubMed

25.

Aigner K, Dampier B, Descovich L et al (2007) The transcription factor ZEB1 (δEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity. Oncogene 26:1–10CrossRef

26.

Wang F, Sloss C, Zhang X, Lee SW, Cusack J (2007) Membrane-bound heparin-binding epidermal growth factor like growth factor regulates E-cadherin expression in pancreatic carcinoma cells. Cancer Res 67:8486–8493CrossRefPubMed

27.

Sharma D, Fondell JD. (2002) Ordered recruitment of histone acetyltransferases and the TRAP/mediator complex to thyroid hormone-responsive promoters in vivo. Proc Natl Acad Sci 99:7394–7399CrossRef

28.

Hall R, Clements J, Birrell S, Tilley W (1998) Prostate-specific antigen and gross cystic disease fluid protein-15 are co-expressed in androgen receptor-positive breast tumours. Br J Cancer 78:360–365PubMed

29.

DiMonaco M, Brignardello E, Leonardi L, Gatto V, Bocuzzi G (1995) Inhibitory effect of hydroxyflutamide plus tamoxifen on oestradiol-induced growth of MCF-7 breast cancer cells. J Cancer Res Clin Oncol 121:710–714CrossRef

30.

Richer J, Jacobsen B, Manning N, Abel M, Wolf D, Horwitz K (2002) Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. J Biol Chem 277:5209–5218CrossRefPubMed

31.

Chamberlain EM, Sanders MM (1999) Identification of the novel player deltaEF1 in estrogen transcriptional cascades. Mol Cell Biol 19:3600–3609PubMed

32.

Singh M, Spoelstra N, Jean A, Howe E, Torkko K, Clark H, Darling D, Shroyer K, Horwitz K, Broaddus R, Richer J (2008) ZEB1 expression in type I vs type II endometrial cancers: a marker of aggressive disease. Mod Pathol 21:1–12CrossRef

33.

Dillner N, Sanders M (2004) Transcriptional activation by the zinc-finger homeodomain protein delta EF1 in estrogen signaling cascades. DNA Cell Biol 23:25–34CrossRefPubMed

34.

Lazarova DL, Bordonaro M, Sartorelli AC (2001) Transcriptional regulation of the vitamin D3 receptor gene by ZEB. Cell Growth Differ 12:319–326PubMed

35.

Sekido R, Murai K, Funashashi J, Kamachi Y, Fujisawa A (1997) Two mechanisms in the action of repressor δEF1: binding site competition with an activator and active repression. Genes Cells 2:771–783CrossRefPubMed

36.

Anose B, LaGoo L, Schwendinger J (2008) Characterization of androgen regulation of ZEB and PSA in 22RV1 prostate cancer cells. Adv Exp Med Biol 617:541–546CrossRefPubMed

Title: Reciprocal regulation of ZEB1 and AR in triple negative breast cancer cells
Authors: Tisheeka R. Graham
Rami Yacoub
LaTonia Taliaferro-Smith
Adeboye O. Osunkoya
Valerie A. Odero-Marah
Tongrui Liu
K. Sean Kimbro
Dipali Sharma
Ruth M. O’Regan
Publication date: 01-08-2010
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2010
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-009-0623-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2010

The fog hasn’t lifted on “chemobrain” yet: ongoing uncertainty regarding the effects of chemotherapy and breast cancer on cognition

Concordance of HER2 in primary tumor and leptomeningeal metastases: now what?

A unique proteolytic fragment of alpha1-antitrypsin is elevated in ductal fluid of breast cancer patient

Concordant HER2 status between metastatic breast cancer cells in CSF and primary breast cancer tissue

Global breast cancer seasonality

COMT Val158Met polymorphism and breast cancer risk: evidence from 26 case–control studies

Keynote webinar | Spotlight on antibody–drug conjugates in cancer